dr. J.C. Oosterwijk

No picture available
j.c.oosterwijk umcg.nl


  1. 2020
  2. Familial MRI Screening (FaMRIsc) Study group, Geuzinge, H. A., Obdeijn, I-M., Rutgers, E. J. T., Saadatmand, S., Mann, R. M., ... de Koning, H. J. (2020). Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. JAMA oncology, E1-E9. https://doi.org/10.1001/jamaoncol.2020.2922
  3. Tilanus-Linthorst, M. M. A., Geuzinge, H. A., Obdeijn, I-M. M., Rutgers, E. J. T., Mann, R. M., Saadatmand, S., ... de Koning, H. J. (2020). Costs and effects in the first randomized trial comparing MRI breast cancer screening with mammography in women with a familial risk: FaMRIsc. Cancer Research, 80(4). https://doi.org/10.1158/1538-7445.SABCS19-GS4-07
  4. GEMO Study Collaborators, EMBRACE Collaborators, kConFab Investigators, HEBON Investigators, & ABCTB Investigators (2020). Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 52(1). https://doi.org/10.1038/s41588-019-0537-1
  5. 2019
  6. HEBON Grp, de Jonge, M. M., Ritterhouse, L. L., de Kroon, C. D., Vreeswijk, M. P. G., Segal, J. P., & Puranik, R. (2019). Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clinical Cancer Research, 25(24), 7517-7526. https://doi.org/10.1158/1078-0432.CCR-19-0848
  7. IMPACT Study Collaborators, Page, E. C., Bancroft, E. K., Brook, M. N., Assel, M., Hassan Al Battat, M., ... Cardoso, M. (2019). Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 76(6), 831-842. https://doi.org/10.1016/j.eururo.2019.08.019
  8. Lakeman, I. M. M., Hilbers, F. S., Rodríguez-Girondo, M., Lee, A., Vreeswijk, M. P. G., Hollestelle, A., ... Devilee, P. (2019). Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families. JOURNAL OF MEDICAL GENETICS, 56(9), 581-589. https://doi.org/10.1136/jmedgenet-2019-106072
  9. FaMRIsc Study Grp, Saadatmand, S., Geuzinge, H. A., Rutgers, E. J. T., Mann, R. M., van Zuidewijn, D. B. W. D. R., ... Tilanus-Linthorst, M. M. A. (2019). MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncology, 20(8), 1136-1147. https://doi.org/10.1016/S1470-2045(19)30275-X
  10. Postema, F. A. M., Bliek, J., van Noesel, C. J. M., van Zutven, L. J. C. M., Oosterwijk, J. C., Hopman, S. M. J., ... Hennekam, R. C. (2019). Multiple tumors due to mosaic genome-wide paternal uniparental disomy. Pediatric blood & cancer, 66(6), [27715]. https://doi.org/10.1002/pbc.27715
  11. Reumkens, K., Tummers, M. H. E., Gietel-Habets, J. J. G., van Kuijk, S. M. J., Aalfs, C. M., van Asperen, C. J., ... van Osch, L. A. D. M. (2019). Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-making. Journal of genetic counseling, 28(3), 533-542. https://doi.org/10.1002/jgc4.1056
  12. GEMO Study Collaborators, Qian, F., Wang, S., Mitchell, J., McGuffog, L., Barrowdale, D., ... Friedman, E. (2019). Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 111(4), 350-364. [132]. https://doi.org/10.1093/jnci/djy132
  13. Reumkens, K., Tummers, M. H. E., Gietel-Habets, J. J. G., van Kuijk, S. M. J., Aalfs, C. M., van Asperen, C. J., ... van Osch, L. A. D. M. (2019). The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study. Familial Cancer, 18(1), 137-146. https://doi.org/10.1007/s10689-018-0092-4
  14. Ausems, M. G. E. M., Oosterwijk, J. C., Nielsen, M., Lolkema, M. P., Hoogerbrugge, N., & Ligtenberg, M. J. L. (2019). Genetisch onderzoek bij patiënten met kanker. Nederlands Tijdschrift voor Geneeskunde, 163.
  15. 2018
  16. EMBRACE, GENEPSO, BCFR, HEBON, kConFab and IBCCS, Terry, M. B., Liao, Y., Kast, K., Antoniou, A. C., McDonald, J. A., ... van Leeuwen, F. E. (2018). The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI cancer spectrum, 2(4). https://doi.org/10.1093/jncics/pky078
  17. Moghadasi, S., Grundeken, V., Janssen, L. A. M., Dijkstra, N. H., Rodriguez-Girondo, M., van Zelst-Stams, W. A. G., ... van Asperen, C. J. (2018). Performance of BRCA1/2 mutation prediction models in male breast cancer patients. Clinical Genetics, 93(1), 52-59. https://doi.org/10.1111/cge.13065
  18. Mikropoulos, C., Selkirk, C. G. H., Saya, S., Bancroft, E., Vertosick, E., Dadaev, T., ... IMPACT Study Collaborators (2018). Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Jounal of Cancer, 118(2), 266-276. https://doi.org/10.1038/bjc.2017.429
  19. IMPACT Study Collaborators, Mikropoulos, C., Hutten Selkirk, C. G., Saya, S., Bancroft, E., Vertosick, E., ... Ruijs, M. (2018). Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 118(6), e17. https://doi.org/10.1038/bjc.2018.11
  20. 2017
  21. van der Tuin, K., Tops, C. M. J., Adank, M. A., Cobben, J-M., Hamdy, N. A. T., Jongmans, M. C., ... Morreau, H. (2017). CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 102(12), 4534-4540. https://doi.org/10.1210/jc.2017-01249
  22. Milne, R. L., Kuchenbaecker, K. B., Michailidou, K., Beesley, J., Kar, S., Lindstrom, S., ... NBSC Collaborators (2017). Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 49(12), 1767-1778. https://doi.org/10.1038/ng.3785
  23. Shimelis, H., Mesman, R. L. S., Von Nicolai, C., Ehlen, A., Guidugli, L., Martin, C., ... NBCS Collaborators (2017). BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 77(11), 2789-2799. https://doi.org/10.1158/0008-5472.CAN-16-2568
  24. 2016
  25. Rebbeck, T. R., Friebel, T. M., Mitra, N., Wan, F., Chen, S., Andrulis, I. L., ... kConFab Investigators (2016). Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast cancer research, 18(112), [112]. https://doi.org/10.1186/s13058-016-0768-3
  26. van Tilborg, T. C., Derks-Smeets, I. A. P., Bos, A. M. E., Oosterwijk, J. C., van Golde, R. J., de Die-Smulders, C. E., ... Broekmans, F. J. M. (2016). Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced? Human Reproduction, 31(11), 2651-2659. https://doi.org/10.1093/humrep/dew242
  27. Vos, J. R., Oosterwijk, J. C., Aalfs, C. M., Rookus, M. A., Adank, M. A., van der Hout, A. H., ... Hereditary Breast Ovarian Canc Res (2016). Bias explains most of the parent-of-origin effect on breast cancer risk in BRCA1/2 mutation carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 25(8), 1251-1258. https://doi.org/10.1158/1055-9965.EPI-16-0182
  28. Sigl, V., Owusu-Boaitey, K., Joshi, P. A., Kavirayani, A., Wirnsberger, G., Novatchkova, M., ... CIMBA (2016). RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell research, 26(7), 761-774. https://doi.org/10.1038/cr.2016.69
  29. Hollestelle, A., van der Baan, F. H., Berchuck, A., Johnatty, S. E., Aben, K. K., Agnarsson, B. A., ... SWE-BRCA (2016). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 141(2), 386-401. https://doi.org/10.1016/j.ygyno.2015.04.034
  30. Dunning, A. M., Michailidou, K., Kuchenbaecker, K. B., Thompson, D., French, J. D., Beesley, J., ... kConFab Investigators (2016). Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 48(4), 374-+. https://doi.org/10.1038/ng.3521
  31. Meeks, H. D., Song, H., Michailidou, K., Bolla, M. K., Dennis, J., Wang, Q., ... PRostate Canc Assoc Grp (2016). BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Jnci-Journal of the national cancer institute, 108(2), [315]. https://doi.org/10.1093/jnci/djv315
  32. 2015
  33. Castro, E., Jugurnauth-Little, S., Karlsson, Q., Al-Shahrour, F., Pineiro-Yanez, E., Van de Poll, F., ... IMPACT Study (2015). High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers. Annals of Oncology, 26(11), 2293-2300. https://doi.org/10.1093/annonc/mdv356
Previous 1 2 3 4 5 Next

ID: 124551